SH2B1 CpG-SNP Is Associated with Body Weight Reduction in Obese Subjects Following a Dietary Restriction Program

2014 ◽  
Vol 66 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Maria Luisa Mansego ◽  
Fermin Ignacio Milagro ◽  
Maria Angeles Zulet ◽  
José Alfredo Martinez
Keyword(s):  
Dna Methylation ◽  
Body Weight ◽  
Weight Reduction ◽  
Molecular Mechanisms ◽  
White Blood Cells ◽  
The Body ◽  
Mrna Levels ◽  
Bdnf Mrna ◽  
Body Weight Reduction ◽  
Obese Subjects

The objective of this study was to examine whether 7 SNPs previously associated with obesity-related traits that add or remove potential sites of DNA methylation are accompanied by differential DNA methylation and subsequently affect adiposity variables or body weight reduction in WBC from obese subjects under an energy-restricted program. Material and Methods: Anthropometric measurements were assessed in 47 volunteers recruited within the RESMENA study (Spain). At baseline, DNA from white blood cells was isolated and 7 obesity-related trait CpG-SNPs were genotyped by TaqMan-PCR. Then, methylation levels of CpG-SNP sites were quantified by MassArray® EpiTyper™ or MS-HRM approaches. Results: Differential DNA methylation levels were observed by genotypes in all of the CpG-SNPs analyzed. The FTO and BDNF methylation levels were further correlated with baseline body weight and, BDNF mRNA levels and body weight change, respectively. Moreover, the rs7359397 (SH2B1) was associated with the body weight, body mass index, and truncal fat mass reduction. Conclusions: Our results reveal the interaction of epigenetic and genetic variations in CpG-SNPs, especially in BDNF and SH2B1 genes, and how allele-specific methylation may contribute to elucidate the possible molecular mechanisms as these SNPs are affecting the decrease of mRNA levels and contributing to a lower body weight reduction. © 2014 S. Karger AG, Basel

scholarly journals Effects of a 3-Week In-Hospital Body Weight Reduction Program on Cardiovascular Risk Factors, Muscle Performance, and Fatigue: A Retrospective Study in a Population of Obese Adults with or without Metabolic Syndrome

Nutrients ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1495 ◽  
Author(s):  
Antonello E. Rigamonti ◽  
Sabrina Cicolini ◽  
Diana Caroli ◽  
Alessandra De Col ◽  
Massimo Scacchi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Weight Loss ◽  
Body Weight ◽  
Weight Reduction ◽  
Hdl Cholesterol ◽  
Muscle Performance ◽  
Weight Reduction Program ◽  
Body Weight Reduction ◽  
Reduction Program ◽  
Obese Subjects

Background. In clinical practice, there is the diffuse conviction that obese subjects with metabolic syndrome may be more difficult to treat. Objectives and Methods. The aim of the present study was that to investigate the effectiveness of a 3-week in-hospital body weight reduction program (BWRP) in a large population of obese subjects with and without metabolic syndrome (n = 1922; 222 men and 1700 women, age range 18–83 yr). Outcomes such as body mass index (BMI), total (TOT) and HDL cholesterol, systolic and diastolic blood pressures (SBP and DBP, respectively), coronary heart disease (CHD) score, fatigue severity score (FSS), and stair climbing test (SCT) time were evaluated before and after the intervention (Δ). A sex-, BMI-, and age-related stratification of the obese population with or without metabolic syndrome was applied. Results. When compared to obese subjects without metabolic syndrome, at the basal conditions, obese subjects had a poorer cardiometabolic profile, as demonstrated by higher triglycerides, TOT-cholesterol, DBP, SBP, and CHD score, and a more compromised muscle performance (evaluated by SCT), associated with more perception of fatigue (measured by FSS). Nevertheless, obese subjects with metabolic syndrome obtained more benefits from BWRP than those without metabolic syndrome for some outcomes (i.e., ΔTOT-cholesterol, ΔSBP, and ΔCHD score). Despite these differences, the BWRP-induced weight loss was similar between the two groups (i.e., ΔBMI) as well as the gain of muscle performance (i.e., ΔSCT) and the reduction of fatigue (i.e., ΔFSS). Interestingly, the potentially deleterious fall in HDL-cholesterol levels after BWRP was less evident in obese subjects with metabolic syndrome than those without metabolic syndrome. When pooling all data, the ΔCHD score was associated with age, sex, and metabolic syndrome. The remaining outcomes, such as ΔBMI, ΔFSS, and ΔSCT time, were associated with sex and age but not with metabolic syndrome. Finally, ΔBMI was positively correlated with ΔCHD score, ΔFSS, and ΔSCT time in both obese subjects without metabolic syndrome and obese subjects with metabolic syndrome. Conclusions. When comparing obese subjects undergoing a BWRP, metabolic syndrome is not a negative predictive factor affecting the effectiveness of this intervention in terms of weight loss, muscle performance, and psychological well-being.

EXERCISE-BASED BODY WEIGHT REDUCTION IMPROVES QT INTERVAL AND QT DISPERSION IN OBESE SUBJECTS

2001 ◽  
Vol 33 (5) ◽  
pp. S336
Author(s):  
K Sasaki ◽  
K Okita ◽  
H Nishijima ◽  
K Yonezawa ◽  
T Nagai ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Reduction ◽  
Qt Interval ◽  
Qt Dispersion ◽  
Body Weight Reduction ◽  
Obese Subjects

scholarly journals Effects of Body Weight Reduction on Serum Irisin and Metabolic Parameters in Obese Subjects

2016 ◽  
Vol 40 (5) ◽  
pp. 386 ◽  
Author(s):  
Yaeko Fukushima ◽  
Satoshi Kurose ◽  
Hiromi Shinno ◽  
Ha Cao Thi Thu ◽  
Nana Takao ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Reduction ◽  
Metabolic Parameters ◽  
Body Weight Reduction ◽  
Obese Subjects

scholarly journals IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Barbara Grube ◽  
Udo Bongartz ◽  
Felix Alt
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Weight Reduction ◽  
Short Term ◽  
Double Blind ◽  
Efficacy Analysis ◽  
Body Weight Reduction ◽  
Obese Subjects ◽  
The Individual ◽  
Primary Efficacy Analysis

The individual ingredients in IQP-VV-102 have demonstrated promising effects in reducing sugar and starch digestion, which potentially leads to weight loss. The trial objective was to evaluate the safety and efficacy of IQP-VV-102 in reducing body weight in overweight and obese subjects. 120 overweight and obese individuals aged 18 to 60 years were randomly assigned to 2 treatment arms (IQP-VV-102 and placebo). The trial was conducted in 2 study centres in Berlin, Germany. The primary efficacy analysis was conducted on 117 subjects (IQP-VV-102:N=54; placebo:N=59), comparing the weight loss effect at baseline and 12 weeks after randomization. There was a statistically significant reduction in mean body weight of 3.29 kg (SD 2.30) in the IQP-VV-102 group compared to 0.83 kg (SD 2.00) in the placebo groupp<0.001. There were no serious or product-related adverse events that were reported over the combined period of 14 weeks. The findings suggested that IQP-VV-102 is effective and safe in body weight reduction in overweight and obese individuals in the short term. The study is registered under clinicaltrials.gov asNCT01681069.

scholarly journals Successful maintenance of body weight reduction after individualized dietary counseling in obese subjects

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Marta Stelmach-Mardas ◽  
Marcin Mardas ◽  
Wojciech Warchoł ◽  
Małgorzata Jamka ◽  
Jarosław Walkowiak
Keyword(s):  
Body Weight ◽  
Weight Reduction ◽  
Dietary Counseling ◽  
Body Weight Reduction ◽  
Obese Subjects
Sign in / Sign up

Export Citation Format

Share Document